Intelligence · Clinical Pipeline
Oncology · Phase III
Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.
- Programs
- 1,266
Quick answer
Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- AstraZeneca 75 programs
- Chinese Academy of 70 programs
- HOFFMANN-LA ROCHE 68 programs
- MSD Merck Sharp 56 programs
- First People's Hospital 53 programs
- Ningbo Cancer Hospital 44 programs
- United Therapeutics Europe 43 programs
- Anaxis Pharma 37 programs
- AstraZeneca 37 programs
- Novartis India 32 programs
- George Institute for 29 programs
- Takeda 28 programs
-
PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
1 trial -
PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.
Partner Therapeutics Limited
Stage IIB-IIIB (N2) resectable non small cell lung cancer
1 trial -
PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN
Merck Sharp and Dohme
Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
1 trial -
PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN
Pari Pharma GmbH
Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)
1 trial -
PEMETREXED, PALONOSETRON, Adagrasib, PEMBROLIZUMAB, CARBOPLATIN, tablets, CISPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Locally Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
PEMETREXED, VINORELBINE, Rilvegostomig, MYCOPHENOLATE MOFETIL, ETOPOSIDE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, Datopotamab deruxtecan
AstraZeneca AB
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature
1 trial -
PF-02341066
Pfizer
Carcinoma, Non-Small-Cell Lung
2 trials -
PF-05280014
Pfizer
Metastatic Breast Cancer
1 trial -
PF-05280586
Pfizer
Follicular Lymphoma
1 trial -
PF-06801591
Pfizer
Non-muscle Invasive Bladder Cancer
1 trial -
PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg
Pfizer Australia Pty Ltd
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
1 trial -
PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB
Wuhan Createrna Science and Technology Co., Ltd
Mantle cell lymphoma
1 trial -
PIRTOBRUTINIB, IDELALISIB, RITUXIMAB, BENDAMUSTINE HYDROCHLORIDE, PIRTOBRUTINIB, IDELALISIB
Wuhan Createrna Science and Technology Co., Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
PIRTOBRUTINIB, RITUXIMAB, PIRTOBRUTINIB, BENDAMUSTINE
Wuhan Createrna Science and Technology Co., Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
PONATINIB, PONATINIB, Ponatinib, IMATINIB, IMATINIB
Takeda
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1 trial -
PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -
Merck Sharp and Dohme
Metastatic Castration-Resistant Prostate Cancer
1 trial -
PREDNISOLONE , Verzenios 50 mg film-coated tablets, Placebo to match LY2835219 (Abemaciclib) Tablets, Placebo to match LY2835219 (Abemaciclib) Capsules, PREDNISONE , ABIRATERONE
Eli Lilly Co.
Prostate Cancer
1 trial -
PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE
Celgene Europe Limited
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1 trial -
PREDNISONE, DOXORUBICIN , BENDAMUSTINE , VINCRISTINE , VINCRISTINE, CYCLOPHOSPHAMIDE , OBINUTUZUMAB, RITUXIMAB, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, BENDAMUSTINE, RITUXIMAB, PREDNISONE , RITUXIMAB, OBINUTUZUMAB
Fondazione Telethon ETS
Follicular Lymphoma
1 trial -
PSMA-11 kit for Ga-68 labelling
Bial Portela & Companhia S.A.
Intermediate and high-risk prostate cancer
1 trial -
PV-10 (10% rose bengal disodium)
PROVECTUS BIOPHARMACEUTICALS, INC.
Cutaneous Melanoma
1 trial -
Paclitaxel
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
Paclitaxel
Cellectar Biosciences
Non Small Cell Lung Cancer
1 trial -
Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion
Gilead Sciences Pty Limited
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1 trial -
Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.
Lacuna Pharma Pty Ltd
Non-small Cell Lung Cancer
1 trial -
Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
Ningbo Cancer Hospital
Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less
1 trial -
Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung
Incyte
Metastatic nonsquamous or squamous non-small cell lung cancer
1 trial -
Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL
Bristol-Myers Squibb Australia Pty Ltd
Stage IV Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Summit Therapeutics
Metastatic Squamous Non-small Cell Lung Cancer
1 trial -
Paclitaxel dosing according to SmPC
BRIGHT MINDS BIOSCIENCES INC.
Carcinoma, Non-Small-Cell Lung
1 trial -
Paclitaxel or docetaxel + Cisplatin or carboplatin
The First People's Hospital of Lianyungang
Uterine Cervical Neoplasms
1 trial -
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine
Teva Pharma GmbH
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1 trial -
Paclitaxel, Cisplatin Plus 5-FU (TCF)
The First People's Hospital of Lianyungang
Esophageal Cancer Stage IIB
1 trial -
Palazestrant
Olema Pharmaceuticals
Breast Cancer
3 trials -
Palazestrant matching placebo tablets and Letrozole matching placebo capsules, Palazestrant, RIBOCICLIB, Palazestrant, -, LETROZOLE , Palazestrant
Olema Pharmaceuticals
ER+, HER2- Advanced Breast Cancer
1 trial -
Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE
Olema Pharmaceuticals
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy
1 trial -
Palbociclib
Pfizer
Metastatic Breast Cancer
1 trial -
Palliative Chemotherapy
Sun Yat-sen University
Colorectal Neoplasms Malignant
1 trial -
Pamiparib capsule
BeiGene
Ovarian Cancer
1 trial -
Pamiparib capsule
BEONE MEDICINES AUS PTY LTD
Ovarian Cancer
1 trial -
Panitumumab
Amgen
Metastatic Colorectal Cancer
1 trial -
Pegylated Interferon Alfa-2a
Hoffmann-La Roche
Chronic Myelogenous Leukemia
1 trial -
Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung
Incyte
Cholangiocarcinoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Ovarian Cancer
1 trial -
Pembrolizumab
Incyte
Renal Cell Carcinoma (RCC)
1 trial -
Pembrolizumab
Eisai Co.,
Endometrial Neoplasms
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Renal Cell Carcinoma
1 trial -
Pembrolizumab
Merck KGaA, Darmstadt, Germany
Cervical Cancer
1 trial
Frequently asked questions
How many oncology Phase III programs exist?
1,266 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs